Weekly Investment Analysts’ Ratings Updates for Spruce Biosciences (SPRB)

A number of firms have modified their ratings and price targets on shares of Spruce Biosciences (NASDAQ: SPRB) recently:

• 12/27/2025 – Spruce Biosciences was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 12/23/2025 – Spruce Biosciences is now covered by analysts at Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $283.00 price target on the stock.
• 12/22/2025 – Spruce Biosciences had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Spruce Biosciences had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $220.00 price target on the stock.
• 12/15/2025 – Spruce Biosciences had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Spruce Biosciences had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/6/2025 – Spruce Biosciences was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 12/3/2025 – Spruce Biosciences was upgraded by analysts at Leerink Partnrs from a “hold” rating to a “strong-buy” rating.
• 12/3/2025 – Spruce Biosciences was upgraded by analysts at Leerink Partners from a “market perform” rating to an “outperform” rating. They now have a $160.00 price target on the stock.
• 12/1/2025 – Spruce Biosciences had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – Spruce Biosciences had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/17/2025 – Spruce Biosciences had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/15/2025 – Spruce Biosciences was upgraded by analysts at Wall Street Zen to a “sell” rating.
• 11/11/2025 – Spruce Biosciences had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/11/2025 – Spruce Biosciences was given a new $259.00 price target on by analysts at JMP Securities.
• 11/11/2025 – Spruce Biosciences had its “market perform” rating reaffirmed by analysts at Citigroup Inc..
• 11/11/2025 – Spruce Biosciences had its price target raised by analysts at Citizens Jmp from $254.00 to $259.00. They now have a “market outperform” rating on the stock.
• 11/5/2025 – Spruce Biosciences had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.

Spruce Biosciences, Inc is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials.

The company’s lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels.